RJ Hamster
Coverage Starting Now: (YDES) Tops Tuesday’s Watchlist—Here’s Why
 Any content you receive is for information purposes only. Always conduct your own research.*SponsoredKrypton Street Puts (YDES) At The Top of This Morning’s Watchlist —Tuesday, January 6, 2026. Coverage Starts Now: See Full Briefing Below Don’t Miss The Next Breakout—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email.Take A Look At (YDES) While It’s Still Early… January 6, 2026 Coverage Starting Now | (YDES) Tops Tuesday’s Watchlist—Here’s WhyDear Reader,A little-known name in biotech has been flashing louder signals lately — and it’s not because of a single headline.It’s because multiple pieces are starting to line up at the same time: expanding U.S. access for a blood-test platform, pushing an eye-care product line into regulated channels, and laying groundwork to scale.That combination is exactly why YD Bio Limited (Nasdaq: YDES) just hit our radar — and why it’s topping our watchlist this morning, Tuesday, January 6, 2026.Now layer in a setup that tends to matter most in the short term: (YDES) reportedly has fewer than 1.5M shares available to the public. When the float is that tight, price action can turn fast when attention increases.And we’ve already seen what that can look like — (YDES) made an approximate +98% move in roughly two weeks, from $7.90 on Nov. 25 to $15.72 on Dec. 8, based on Barchart data.  The headlines aren’t about one isolated milestone — they’re about multiple tracks advancing at once.And when that happens, it often signals a company trying to shift from “concept” to “execution.”Here’s what the latest developments reveal.YD Bio Limited (Nasdaq: YDES) is a biotechnology company advancing DNA methylation cancer detection and ophthalmologic innovations.In company materials, (YDES) highlights three areas: DNA methylation-based cancer detection (EG BioMed), ophthalmology therapies and products (3D Global Biotech), and clinical trial support.Quick “Market Map” for (YDES)Two of (YDES)’s main focus areas — blood-based cancer testing and eye-care products — point toward large, expanding markets:Cancer testing Liquid biopsy: $11.85B (2024) → $22.88B (2030) (+93% total growth potential) MCED (subset): $1.12B (2024) → $2.86B (2030) (+155% total growth potential) Eye-care Contact lenses: $20.5B (2025) → $28.9B (2034) (+41% total growth potential) Dry eye treatment: $6.29B (2024) → $9.20B (2030) (+46% total growth potential)Future market potential: $22.88B + $9.20B + $28.9B = $61B With that market backdrop in mind, the next question is execution.And the company’s latest updates show its OkaiDx™ platform moving fast in the U.S.OkaiDx™ Cancer Detection Platform: Rapid U.S. Expansion  On Dec. 2, 2025, (YDES) said it expanded its OkaiDx™ blood test program to include pancreatic and colorectal cancer across 44 U.S. states, using its partner EG BioMed’s U.S. lab and a system designed to make access easier (including telehealth and at-home blood collection).The company also shared study results for its pancreatic cancer test, reporting strong performance in early-stage cases — while noting the test is not FDA-cleared and is still being validated.Earlier, on Nov. 5, 2025, the company said OkaiDx was also made available in the U.S. for post-treatment breast cancer monitoring as a research-use-only option.And on Oct. 10, 2025, the company highlighted that its partner EG BioMed’s U.S. lab received a major quality accreditation — a step the company positioned as supportive for rolling out advanced testing services.U.S. Eye-Care Market EntryOn Nov. 24, 2025, (YDES) announced its first commercial entry into U.S. eye care through partner 3D Global Biotech, highlighting two products:Exovisse Contact Lenses, described as cleared for U.S. marketing through the FDA’s 510(k) process Nov 24, 2025Exovisse Artificial Tears, described as aligned with FDA OTC requirements, which the company said enables broad U.S. distribution Nov 24, 2025The same release also stated that (YDES)’s limbal stem cell (LSC) materials and related exosomes were included in an FDA reference filing (Dr-ug Master File), which the company framed as supportive for future therapeutic development.It also described plans tied to dry eye disease and additional retinal/macular applications.International Presence + U.S. Expansion On Dec. 9, 2025, (YDES) said it participated in Healthcare Expo Taiwan and held discussions with potential distributors from China, Hong Kong, Indonesia, and Dubai, who expressed interest in expanding the company’s cancer detection and eye-care portfolios in their regions.Then on Dec. 16, 2025, the company announced plans for a California operations center (still in the site-evaluation stage) intended to support clinical collaboration, regulatory work, and overall commercialization readiness in the U.S.Strategic Partnerships In its own materials, (YDES) emphasizes that its strategy relies heavily on partnerships — including EG BioMed for its cancer testing programs and 3D Global Biotech for its eye-care products and therapeutic development direction.In short: (YDES) is presenting a story where a blood-test platform expands across U.S. markets while an eye-care product line enters regulated U.S. sales channels, with additional infrastructure plans to support broader scale over time.7 Factors Putting (YDES) At The Top Of This Morning’s Watchlist —Tuesday, January 6, 2026 1. Recent Momentum: A recent move of roughly +98% in about two weeks puts (YDES) on the radar for momentum-focused research.2. Small Float: With fewer than 1.5M shares reportedly available to the public, (YDES)’s small float could see the potential for big moves if demand begins to shift.3. Growth Backdrop: The key categories around (YDES) show significant projected expansion over the next several years, including liquid biopsy and dry eye treatment.4. U.S. Expansion: The company says (YDES) expanded its OkaiDx™ program across 44 U.S. states, supported by a U.S. lab partner and broader access options.5. Regulated Products: In eye care, (YDES) has highlighted products described as cleared or aligned with U.S. regulatory pathways for broad distribution.6. Partner Leverage: The strategy described for (YDES) relies on partners like EG BioMed and 3D Global Biotech, which the company presents as a way to accelerate execution.7. Massive TAM: The cancer-testing and eye-care categories tied to (YDES) add up to an estimated $61B future market potential based on published projections.Take A Look At (YDES) While It’s Still Early…  What makes (YDES) so compelling right now is the combination of near-term attention drivers and a big-picture market backdrop.With a reported public float under 1.5M shares, the name can react quickly when interest builds — and the recent +98% move (approx.) in about two weeks shows it already has the ability to draw momentum.At the same time, the company is positioning itself across categories that add up to an estimated $61B in future market potential, with industry forecasts pointing to meaningful growth in areas like liquid biopsy and dry eye treatment.Add in the company’s stated expansion of OkaiDx™ access across 44 U.S. states, plus eye-care products described as cleared or aligned with U.S. regulatory pathways, and it’s easy to see why this story is gaining traction.Finally, (YDES) continues to emphasize partner-driven execution — leaning on groups like EG BioMed and 3D Global Biotech as it pushes forward.We’re watching (YDES) very closely this morning.Give (YDES) a quick look while it’s still early.And keep an eye out for my next update, it could be hitting before the bell rings.Sincerely,Alex RamsayCo-Founder / Managing EditorKrypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KS is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 01/05/2026 and ending on 01/06/2026 to publicly disseminate information about (YDES:US) via digital communications. Under this agreement, Media 1717 LLC has been paid seven thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.Neither Media 1717 LLC, TD Media LLC and their member own shares of (YDES:US).Please see important disclosure information here: https://kryptonstreet.com/disclosure/ydes-um0ce/#details |
| Media 1717 LLC | 6586 W Atlantic Ave, Unit #2086, Delray Beach, FL 33446UnsubscribeUpdate Profile | Constant Contact Data NoticeSent by alex@kryptonstreet.com |
